An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome

NCT02117713 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Alagille Syndrome

Interventions

DRUG: LUM001 (Maralixibat)

Sponsor

Mirum Pharmaceuticals, Inc.

Collaborators

[object Object]
[object Object]